Humira buyers appeal AbbVie ruling to Seventh Circuit
31-07-2020
Clean sweep for AbbVie in Humira litigation
15-05-2019
AbbVie and Pfizer in Humira licensing deal
03-12-2018
AbbVie secures another Humira settlement
12-10-2018
casimiropt / Shutterstock.com
AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira (adalimumab).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
AbbVie, Humira, antitrust, competition, licensing deals, patent thickets, Pfizer, Sandoz, Mylan, biosimilars
